HER2

On target clinical trial success bullseye score

AstraZeneca's breast cancer pill boosts PFS by 56% in phase 3

AstraZeneca has produced data to back up blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival

James Waldron Jun 2, 2025 7:10am

Enliven calls time on phase 1 HER2 solid tumor program

May 15, 2025 7:50am

Boehringer flexes staying power of HER2-mutant lung cancer med

Apr 28, 2025 9:00am

part ways switch off track cancel end path

Eisai's abandoned Enhertu challenger set to live on at BlissBio

Mar 21, 2025 7:20am

Roche companion test moves into HER2-ultralow breast cancer

Feb 4, 2025 12:00pm

OS' drug stopped lung cancer from returning in 3rd of patients

Jan 15, 2025 9:55am